Fears that Adriatic’s statistical survival wins would be clinically marginal haven’t materialised.

SEZ6 looks promising but early, while questions remain around toxicity with AbbVie's cMet ADCs.

The $1bn price tag for the preclinical Mariana Oncology shows that competition for assets in this space is fierce.

Abstract titles reveal some of ASCO’s key datasets.

The group was a first mover in stage III NSCLC, and now it hopes to repeat the trick in SCLC.

New listings reveal expanded phase 3 programmes for J&J’s Talvey and Amgen’s tarlatamab.

A $680m swoop for Harpoon will fill a hole in Merck’s pipeline.

Another KRAS G12D inhibitor hits the clinic, while Zai Lab hopes to banish the spectre of Rova-T.